Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study
Authors:
- Eric BonnetEBEric Bonnet
- Jean-Bernard RuidavetsJRJean-Bernard Ruidavets
- Anne GenouxAGAnne Genoux
- Laurence MabileLMLaurence Mabile
- Florian BusatoFBFlorian Busato
- Martine ObadiaMOMartine Obadia
- François PrévoteauFPFrançois Prévoteau
- Bruno MarchouBMBruno Marchou
- Patrice MassipPMPatrice Massip
- Fabrice Marion-LatardFMFabrice Marion-Latard
- Cyrille DelpierreCDCyrille Delpierre
- Jacques BernardJBJacques Bernard
Open Access
- 28 June 2013
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 293
Abstract
HIV-infected patients starting antiretroviral treatment (ART) experience deep and early disorders in fat and bone metabolism, leading to concomitant changes in fat mass and bone mineral density. We conducted a prospective study in treatment-naive HIV-infected patients randomized to receive two nucleoside reverse transcriptase inhibitors in combination with either a protease inhibitor (PI) or a non-nucleosidic reverse transcriptase inhibitor (NNRTI), to evaluate early changes in body composition, bone mineral density and metabolic markers as differentially induced by antiretroviral therapies. We measured changes in markers of carbohydrate, of fat and bone metabolism, and, using dual-emission X-ray absorptiometry (DXA), body composition and bone mineral density (BMD). Complete data on changes between baseline and after 21 months treatment were available for 35 patients (16 in the PI group and 19 in the NNRTI group). A significant gain in BMI and in total and lower limb fat mass was recorded only in patients receiving PI. A loss of lumbar BMD was observed in both groups, being higher with PI. Plasma markers of bone metabolism (alkaline phosphatase, osteocalcin, collagen crosslaps) and levels of parathormone and of 1,25diOH-vitamin D3 significantly increased in both groups, concomitant with a decline in 25OH-vitamin D3. Lipids and glucose levels increased in both groups but rise in triglyceride was more pronounced with PI. A correlation between loss of BMD and gain of fat mass is observed in patients starting PI. We evidenced an early effect of ART on lipid and bone metabolisms. PI lead to a significant gain in fat mass correlated with a sharp drop in BMD but active bone remodelling is evident with all antiretroviral treatments, associated with low vitamin D levels and hyperparathyroidism. In parallel, signs of metabolic restoration are evident. However, early increases in lean and fat mass, triglycerides, waist circumference and leptin are much more pronounced with PI.Keywords
This publication has 47 references indexed in Scilit:
- Insulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional studyBMC Endocrine Disorders, 2013
- HIV: Inflammation and BoneCurrent HIV/AIDS Reports, 2011
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202The Journal of Infectious Diseases, 2011
- Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimenAIDS Research and Therapy, 2010
- Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?AIDS Research and Therapy, 2009
- Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare SystemThe Journal of Clinical Endocrinology & Metabolism, 2008
- Longitudinal Analysis of Bone Density in Human Immunodeficiency Virus-Infected WomenThe Journal of Clinical Endocrinology & Metabolism, 2006
- Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti‐Retroviral Therapy for AIDSAnnals of the New York Academy of Sciences, 2006
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- BMD Is Reduced in HIV-Infected Men Irrespective of TreatmentJournal of Bone and Mineral Research, 2004